Opinion|Videos|November 1, 2024
Logistical Barriers in Implementing GPRC5D-Targeted Therapies
Panelists discuss how logistical barriers like drug access, insurance coverage, and managing infusion logistics have posed challenges in the implementation of GPRC5D-targeted therapies in community practice.
Advertisement
Episodes in this series
- What logistical barriers have you encountered in implementing GPRC5D-targeted therapies in your community practice (e.g., access, coverage, infusion logistics)?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5